ATE168009T1 - Hypertone isochlorämische formulierung zur behandlung des kreislaufschocks - Google Patents

Hypertone isochlorämische formulierung zur behandlung des kreislaufschocks

Info

Publication number
ATE168009T1
ATE168009T1 AT92917365T AT92917365T ATE168009T1 AT E168009 T1 ATE168009 T1 AT E168009T1 AT 92917365 T AT92917365 T AT 92917365T AT 92917365 T AT92917365 T AT 92917365T AT E168009 T1 ATE168009 T1 AT E168009T1
Authority
AT
Austria
Prior art keywords
isochloremic
hypertone
formulation
treatment
circular shock
Prior art date
Application number
AT92917365T
Other languages
English (en)
Inventor
Mauricio Rocha-E-Silva
Irineu T Velasco
George C Kramer
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of ATE168009T1 publication Critical patent/ATE168009T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
AT92917365T 1991-05-31 1992-04-27 Hypertone isochlorämische formulierung zur behandlung des kreislaufschocks ATE168009T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/708,029 US5248507A (en) 1991-05-31 1991-05-31 Hypertonic isochloremic formulation for circulatory shock

Publications (1)

Publication Number Publication Date
ATE168009T1 true ATE168009T1 (de) 1998-07-15

Family

ID=24844101

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92917365T ATE168009T1 (de) 1991-05-31 1992-04-27 Hypertone isochlorämische formulierung zur behandlung des kreislaufschocks

Country Status (9)

Country Link
US (2) US5248507A (de)
EP (1) EP0587815B1 (de)
JP (1) JPH0714882B2 (de)
AT (1) ATE168009T1 (de)
AU (1) AU654720B2 (de)
CA (1) CA2103246A1 (de)
DE (1) DE69226184T2 (de)
IL (1) IL101773A (de)
WO (1) WO1992021356A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5416078A (en) * 1990-03-30 1995-05-16 Biomedical Frontiers, Inc. Fluid resuscitation
US5248507A (en) * 1991-05-31 1993-09-28 Board Of Regents, The University Of Texas System Hypertonic isochloremic formulation for circulatory shock
US6017953A (en) * 1993-12-28 2000-01-25 Allergan Sales, Inc. Thromboxane ligands
US6566326B1 (en) * 1996-03-13 2003-05-20 The Regents Of The University Of California Chemically modified hemoglobin for burn shock resuscitation
WO1998008500A1 (en) * 1996-08-26 1998-03-05 Board Of Regents, The University Of Texas System Hypertonic arginine compositions and methods
CN1068778C (zh) * 1998-05-15 2001-07-25 赵超英 救治用的药物组合物及其制备方法
GB0011202D0 (en) 2000-05-09 2000-06-28 Kci Licensing Inc Abdominal wound dressing
DE60109184T2 (de) * 2000-10-16 2005-12-29 Universite De Liege Medizinische zusammensetzung und insbesondere seine verwendung in der flüssigkeitstherapie
DE602004002585T2 (de) * 2003-05-01 2007-10-25 Innogene Kalbiotech Pte. Ltd. Laktathaltige pharmazeutische Zusammensetzung und deren Verwendungen
US20050100637A1 (en) * 2003-11-12 2005-05-12 Robert Murray Carbohydrate and electrolyte replacement composition
EP2007371A4 (de) * 2006-04-03 2009-07-22 Innogene Kalbiotech Pte Ltd Lactat und calciumhaltige pharmazeutische zusammensetzung und ihre verwendungen
US8551075B2 (en) 2006-06-02 2013-10-08 Kci Medical Resources Assemblies, systems, and methods for vacuum assisted internal drainage during wound healing
WO2007142688A1 (en) 2006-06-02 2007-12-13 Bengtson Bradley P Assemblies, systems, and methods for vacuum assisted internal drainage during wound healing
US7699831B2 (en) 2006-06-02 2010-04-20 Surgical Design Solutions, Llc Assemblies, systems, and methods for vacuum assisted internal drainage during wound healing
CN101164530B (zh) * 2006-10-18 2010-10-20 周方强 含稳定的丙酮酸钠的水溶液及其制法和用途
CN107865985B (zh) 2008-09-18 2023-04-28 3M创新知识产权公司 用于控制炎症反应的系统和方法
EP2340065B1 (de) 2008-10-29 2015-08-12 KCI Licensing, Inc. Systeme und verfahren mit verringertem druck zum verschluss und zur behandlung von wunden
US8216197B2 (en) 2008-10-29 2012-07-10 Kci Licensing, Inc Medical canister connectors
US8435590B2 (en) * 2008-11-24 2013-05-07 Stokely-Van Camp, Inc. Use of novel carbohydrates and carbohydrate blends to provide a sports beverage with increased absorption
WO2011112166A1 (en) * 2010-03-12 2011-09-15 Scott Cordray Method of treatment
EP2382993A1 (de) 2010-04-19 2011-11-02 KTB Tumorforschungsgesellschaft mbH Kombination von Arzneimitteln mit proteinbindenden Prodrugs
CN103830166B (zh) * 2012-11-22 2015-07-15 北京四环制药有限公司 一种高渗复苏液的制备方法及其应用
US10124021B2 (en) 2016-12-23 2018-11-13 Andrew L. Gostine Intravenous fluid
US12419850B1 (en) 2024-03-21 2025-09-23 GanD, Inc. Bioactive fluid compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4049795A (en) * 1971-05-14 1977-09-20 Centre D'etudes Experimentales Et Cliniques De Physio Biologie De Pharmacologie Et D'eutonologie Treatment of hemorrhagic shock
US3993750A (en) * 1974-12-20 1976-11-23 Research Corporation Aqueous hypertonic solution and compositions useful for preparation of same
US4908350A (en) * 1985-10-31 1990-03-13 The Regents Of The University Of California Hyperosmotic/hyperoncotic solutions for resuscitation of hypodynamic shock
US4927806A (en) * 1987-04-23 1990-05-22 The Regents Of The University Of California Saturated salt/concentrated dextran formulation to treat hemorrhage
US5248507A (en) * 1991-05-31 1993-09-28 Board Of Regents, The University Of Texas System Hypertonic isochloremic formulation for circulatory shock

Also Published As

Publication number Publication date
US5443848A (en) 1995-08-22
JPH0714882B2 (ja) 1995-02-22
EP0587815A1 (de) 1994-03-23
DE69226184T2 (de) 1999-04-08
EP0587815B1 (de) 1998-07-08
IL101773A (en) 1996-06-18
WO1992021356A1 (en) 1992-12-10
DE69226184D1 (de) 1998-08-13
CA2103246A1 (en) 1992-12-01
US5248507A (en) 1993-09-28
JPH06500130A (ja) 1994-01-06
AU654720B2 (en) 1994-11-17
AU1872892A (en) 1993-01-08
IL101773A0 (en) 1992-12-30

Similar Documents

Publication Publication Date Title
ATE168009T1 (de) Hypertone isochlorämische formulierung zur behandlung des kreislaufschocks
Lever et al. Pressure reversal of anaesthesia
CA2181048A1 (en) A method for sustained and extended corneal analgesia
EP1365778A4 (de) Behandlung von lungenerkrankungen mit gasförmigem mittel, das zur verarmung von gsno führt
ES2185646T3 (es) Soluciones de aminoacido mejoradas para el tratamiento de pacientes de dialisis peritoneal.
US11786561B2 (en) Approach to sustained production and delivery of nitric oxide and s-nitrosothiols
ES2037136T3 (es) Procedimiento para la preparacion de una solucion con elevada actividad volumetrica de una proteina con actividad de activador de plasminogeno de tejidos (t-pa).
DE69430813D1 (de) Verwendung eines inositoltriphosphatesters zur behandlung von entzündungen
ATE172117T1 (de) Verwendung von trospiumchlorid zur herstellung eines arzneimittels zur behandlung von blasenkrankheiten
PE33396A1 (es) Composicion para el tratamiento del ansia de nicotina y/o los sintomas de abstinencia de fumar
MX9205568A (es) Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida.
DK1673074T3 (da) Flydende præparat, indeholdende tobramycin
DE69220821D1 (de) Verfahren zur Sicherstellung eines angemessenen intrazellulären Glutathionspiegels im Gewebe
Platt et al. Intraperitoneal antiseptics in experimental bacterial peritonitis
Liebowitz et al. Anaphylactic reaction to chymotrypsin
RU98101223A (ru) Способ профилактики и лечения заболеваний полости рта
JPS57128635A (en) Pharmaceutical preparation of gamma-globulin for venoclysis
JPS6216409A (ja) 塩化ナトリウム入り美容剤
Rammelkamp et al. Hemolytic Effect of Tyrothricin.
Orifkhujaeva Use of Ozone Therapy in the Treatment of Diseases of the Mucous Membrane of the Oral Cavity
MD2354G2 (ro) Metodă de tratament al encefalopatiei hepatice
SE9302006D0 (sv) Protein formulation
Jacoby The toxicity of sulphadiazine and sulphaguanidine to macrophages in vitro
RU94003002A (ru) Способ пролонгации терапевтического эффекта тимолола
Krayer Action of l-Ascorbic Acid upon the Isolated Frog Heart.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties